主页 / 药理学 / Enzymes / Dehydrogenases / Other Dehydrogenases / Other Dehydrogenase Activators / Ranolazine dihydrochloride

Ranolazine dihydrochloride

Cat. No. 3118 3 篇引用文献 2 条评论 提交评论 说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）
Pricing Availability   Qty
说明： Antianginal, activates pyruvate dehydrogenase
别名： RS 43285
化学名： N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride
纯度： ≥98% (HPLC)
说明书
引用文献 (3)
评论 (2)
文献 (2)
生物活性 技术数据 溶解性 计算器 说明书 参考文献

生物活性 for Ranolazine dihydrochloride

Ranolazine dihydrochloride is an antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late INa and IKr currents.

化合物库 for Ranolazine dihydrochloride

Ranolazine dihydrochloride is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. 了解 Tocris 化合物库的更多信息。

技术数据 for Ranolazine dihydrochloride

分子量 500.46
公式 C24H33N3O4.2HCl
储存 Desiccate at RT
纯度 ≥98% (HPLC)
CAS Number 95635-56-6
PubChem ID 71279
InChI Key RJNSNFZXAZXOFX-UHFFFAOYSA-N
Smiles COC1=CC=CC=C1OCC(CN2CCN(CC(NC3=C(C)C=CC=C3C)=O)CC2)O.Cl.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Ranolazine dihydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
water 50.05 100
DMSO 50.05 100

制备储备液 for Ranolazine dihydrochloride

以下数据基于产品分子量 500.46。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2 mL 9.99 mL 19.98 mL
5 mM 0.4 mL 2 mL 4 mL
10 mM 0.2 mL 1 mL 2 mL
50 mM 0.04 mL 0.2 mL 0.4 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for Ranolazine dihydrochloride

分析证书/产品说明书
选择另一批次：
化学品安全技术说明书

参考文献 for Ranolazine dihydrochloride

参考文献是支持产品生物活性的出版物。

Zacharowski et al (2001) Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur.J.Pharmacol. 418 105 PMID: 11334871

Shryock and Belardinelli (2008) Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br.J.Pharmacol. 153 1128 PMID: 18071302

Wang et al (2008) Antitorsadogenic effects of (+/-)-N-(2,6-dimethyl-phenyl)-4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J.Pharmacol.Exp.Ther. 325 875 PMID: 18322148

If you know of a relevant reference for Ranolazine dihydrochloride, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Other Dehydrogenase Activators

关键词: Ranolazine dihydrochloride, Ranolazine dihydrochloride supplier, Anti-anginal, activates, pyruvate, dehydrogenase, anti-arrhythmic, agent, activators, Enzyme, Substrates, RS43285, RS, 43285, Other, Dehydrogenases, /, Activators, Miscellaneous, Compounds, 3118, Tocris Bioscience

3 篇 Ranolazine dihydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Ranolazine dihydrochloride 的部分引用包括：

McKeithan et al (2017) An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. Front Physiol 8 766 PMID: 29075196

Park et al (2013) Slowly inactivating component of Na+ current in peri-somatic region of hippocampal CA1 pyramidal neurons. J Neurophysiol 109 1378 PMID: 23236005

Carstensen et al (2019) Effects of UK 68798 and RS 43285 on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation. J Cardiovasc Electrophysiol 30 596 PMID: 30661267

您是否知道使用了 Tocris Ranolazine dihydrochloride 的优秀论文？ 请告知我们.

Ranolazine dihydrochloride 的评论

平均评分: 5 (基于 2 条评论。)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used Ranolazine dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Reversal of HOCl-LDL induced arrhythmia by ranolazine superfusion.
By Chintan Koyani on 10/22/2018
分析类型： In Vitro
种属： Other
细胞系/组织： Cardiomyocytes

Guinea pig ventricular cardiomyocytes were treated (12-16 h) with HOCl-LDL (250 µg/ml). Cells were patched and stimulated at a frequency of 1 Hz. Representative action potentials (shown in Image) recorded in the same cell are shown before (A) and after (B) superfusion with Ranolazine (10 µM, 5 min). For comparative purpose representative APs of a control cardiomyocyte are shown (C).

review image
Ranolazine to block fatty acid oxidation.
By Anonymous on 01/30/2018
分析类型： Ex Vivo
种属： Mouse
细胞系/组织： Brain slice

Application of Ranolazine on acute brain slices to verify for fatty acid oxidation involvement in studied process. It had the same effect as etomoxir (CPT1 blocker), as expected per hypothesis.

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。

Cancer Metabolism Research Product Guide

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.